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Patients with acute respiratory distress syndrome (ARDS) often develop severe diaphragmatic and limb skeletal
muscle dysfunction. Impaired muscle function in ARDS is associated with increased mortality, increased duration of
mechanical ventilation, and functional disability in survivors. In this review, we propose that muscle dysfunction in
ARDS can be categorized into an early and a late phase. These early and late phases are based on the timing in
relationship to lung injury and the underlying mechanisms. The early phase occurs temporally with the onset of
lung injury, is driven by inflammation and disuse, and is marked predominantly by muscle atrophy from increased
protein degradation. The ubiquitin-proteasome, autophagy, and calpain-caspase pathways have all been implicated
in early-phase muscle dysfunction. Late-phase muscle weakness persists in many patients despite resolution of lung
injury and cessation of ongoing acute inflammation-driven muscle atrophy. The clinical characteristics and mechanisms
underlying late-phase muscle dysfunction do not involve the massive protein degradation and atrophy of the early
phase and may reflect a failure of the musculoskeletal system to regain homeostatic balance. Owing to these
underlying mechanistic differences, therapeutic interventions for treating muscle dysfunction in ARDS may differ
during the early and late phases. Here, we review clinical and translational investigations of muscle dysfunction in
ARDS, placing them in the conceptual framework of the early and late phases. We hypothesize that this conceptual
model will aid in the design of future mechanistic and clinical investigations of the skeletal muscle system in ARDS and
other critical illnesses.Introduction
Improvements in general critical care and ventilator
management of acute respiratory distress syndrome
(ARDS) over the past four decades have led to a signifi-
cant reduction in mortality, from 80 % in the initial re-
ports to the current rate of 20 % to 30 % reported in
clinical trials [1]. These trends have resulted in a grow-
ing number of ARDS patients who are ICU survivors:
approximately 200,000 people per year in the United
States alone [2]. Unfortunately, these patients commonly
have lasting sequelae, including increased mortality [3–5],
physical and cognitive impairment [6–8], and reduced* Correspondence: dfiles@wakehealth.edu
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in clinical trials, the skeletal muscle system has been in-
creasingly recognized as a major target organ in ARDS.
Clinically apparent skeletal muscle weakness in the critic-
ally ill, termed ICU-acquired weakness (ICUAW) [10, 11],
occurs in up to 60 % of patients and is independently as-
sociated with mortality [12, 13].
We propose, on the basis of observations of animal
models and clinical studies, that muscle wasting in pa-
tients with ARDS can be divided into early and late
phases. These phases differ in pathophysiology and po-
tential underlying mechanisms and can be identified by
their relationship to the time course of lung injury, re-
covery, and resolution. In this review, we will summarize
major recent findings regarding clinical and mechanistic
investigations into muscle wasting in ARDS and frame
them in the context of the early and late phases. We
propose that this conceptual framework will enhance thele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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and aid in tailoring therapies designed to treat muscle
wasting in ARDS.
ARDS is the more severe end of the spectrum of dis-
eases requiring admission to an ICU. Although the
muscle-wasting response of patients with ARDS has not
been explicitly compared with that of critically ill pa-
tients without ARDS (that is, sepsis), patients with
ARDS appear to have a very high incidence of ICUAW
(up to 60 %) [12–15]. While the animal studies offer
some clues to mechanistic differences between muscle
wasting in ARDS and sepsis [16], further carefully con-
trolled human studies are needed to determine whether
clinical differences exist in the muscle injury and recov-
ery trajectories of sepsis patients with and without con-
comitant ARDS. For these reasons, in this review, we
will focus primarily on muscle wasting in ARDS, al-
though we feel that this paradigm may prove useful in
other critical illnesses, such as sepsis.
The diagnosis of intensive care unit-acquired
weakness
Since the original report by MacFarlane and Rosenthal
[17], muscle wasting associated with critical illness has
been called acute quadriparetic myopathy, thick filament
myopathy, critical illness myopathy, critical illness poly-
neuropathy, and ICU-acquired paresis, among other
terms. These names reflect the varying associated patho-
logic and electrophysiologic characteristics. The nomen-
clature has recently been simplified, and the term
ICUAW signifies clinically measureable weakness in a
critically ill patient without other known precipitating
factors causing nerve or muscle injury [10, 11].
The diagnosis of ICUAW is made by using either
manual muscle testing (MMT) or grip strength meters
and by using specified cutoff values to denote weakness.
Unfortunately, MMT is effort-dependent and insensitive
and likely under-represents the degree of muscle dys-
function present in these patients [18–20]. MMT, grip
strength meters, and hand-held dynamometers also all
lack the ability to clearly discern muscle fatigability, which
may contribute to the long-term functional impairments
in ICU survivors. Other functional tests - such as the
short physical performance battery [21], six-minute walk
distance [8], or walk speeds [22] - may provide more in-
formation about global function, although these compos-
ite functional tests can be affected by factors other than
muscle dysfunction and require a cooperative, engaged
patient.
Given the limitations of these volitional measurements
of muscle function in critically ill patients and survivors,
other methods for identifying ICUAW are needed.
Nerve conduction and direct muscle stimulation may
improve the sensitivity of diagnosing ICUAW in thenon-cooperative patient [23] but are infrequently used at
present. Skeletal muscle ultrasound is a promising mo-
dality that can non-invasively identify the loss of muscle
mass in critically ill patients; muscle echointensity values
may yield additional functional information [24, 25].
These modalities remain promising, although further re-
search is needed in this area.
Systemic ‘biomarkers’ of ICUAW would also be help-
ful in identifying ICUAW. Creatine phosphokinase, the
most common laboratory test used for identification of
myositis in other contexts, is not helpful in identifying
patients with ICUAW [11, 15]. In a pilot study, peak
plasma neurofilament levels were higher in patients with
ICUAW, but peak levels were not reached before pa-
tients could engage in MMT, limiting the utility of this
as a biomarker [26]. Another study of post-cardiac sur-
gery patients found that insulin-like growth factor 1
(IGF-1) levels were suppressed in patients who devel-
oped ICUAW but that growth and differentiation factor
15 levels were elevated [27]. Additional studies are
needed to identify systemic biomarkers that can reliably
identify patients at high risk for developing ICUAW.
Identifying such patients may assist in targeted allocation
of physical therapy or future pharmacologic interventions.
Phases of muscle dysfunction in acute respiratory
distress syndrome
Definition of the early phase
The early phase of muscle dysfunction, which occurs
hours to days after the onset of illness, begins with the
activation of acute lung and systemic inflammation char-
acteristic of early lung injury. We define the early phase
to begin with the onset of the acute illness and terminate
when the acute inflammation-driven muscle atrophy
program resolves (Fig. 1), usually within days.
Muscle atrophy is the predominant and characteristic
feature of early-phase muscle dysfunction and is driven
primarily by (a) acute systemic inflammation and (b)
limb and diaphragmatic muscle disuse from enforced
bed rest and mechanical ventilation, respectively. Nerve,
neuromuscular junction (NMJ), or direct myofiber injury
or a combination of these may variably initiate atrophy
or contribute to muscle weakness during the early phase.
Considering the ubiquity of inflammation- and immobility-
induced atrophy in these patients, we hypothesize that all
patients with ARDS experience early-phase muscle wast-
ing. We propose that atrophy is the most universal feature
of ICUAW, although other pathologies such as inflamma-
tory myopathies, polyneuropathies, or combinations also
occur. Factors such as age, illness severity, organ failures,
medications, malnutrition, and hypoxia may drive the se-
verity or type of muscle dysfunction in an ancillary fashion.
The drivers and clinical significance of these differing phe-
notypes are poorly understood. However, it is clear that
Fig. 1 The early and late phases of muscle wasting in acute respiratory distress syndrome. The early phase of muscle wasting begins with the
onset of lung injury and is caused by lung and systemic inflammation and to a lesser degree disuse, both leading to muscle atrophy. The late
phase of muscle wasting begins as lung function recovers and acute systemic inflammation resolves. Disuse continues in many patients during
the late phase. Muscle function deteriorates in the early phase, and dysfunction persists in many patients during the late phase, which may last
for years despite resolution of lung injury and cessation of ongoing muscle atrophy. Factors mediating recovery trajectories in the late phase are
poorly understood
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ness, regardless of the pathophysiology, independently con-
tribute to early-phase mortality.
Definition of the late phase
The late phase of muscle dysfunction begins following reso-
lution of the early acute lung and systemic inflammation
characteristic of the early phase, usually following the first
few days of illness and during the recovery phase of lung in-
jury. Muscle atrophy may continue into the late phase,
driven by disuse, but this factor usually resolves once pa-
tients are no longer bedridden. Similar to early-phase wast-
ing, late-phase muscle weakness may occur from persistent
or unresolved nerve or NMJ injury [30, 31].
The characteristic feature of late-phase muscle wasting
is that muscle dysfunction persists despite recovery and
resolution of lung injury in many patients [8, 20]. Factors
such as age, baseline (pre-ARDS) muscle function, medi-
cations administered during or after the ICU stay, comor-
bidities, route of muscle injury (nerve versus NMJ versus
myofiber), and nutrition may contribute to both the de-
gree of injury and the rate of muscle functional recovery.
However, the clinical characteristics associated with
complete, partial, or failed recovery of muscle function in
ARDS survivors (Fig. 1) are generally poorly understood.One fundamental question is whether the recovery of
muscle function in the late phase is associated with re-
covery of muscle mass or alternately whether weakness
persists despite recovery of muscle mass. Answering this
question would clarify potential mechanisms underlying
persistent late-phase weakness. Unfortunately, since pre-
hospital functional status of these patients is almost al-
ways unknown, it is difficult to know how baseline
muscle function contributes to long-term functional out-
comes. In many patients, the ‘failure to recover’ may re-
flect their baseline functional status pre-ARDS.
Prolonged metabolic disturbances and immune sup-
pression have been described in survivors of burns [32]
and sepsis [33]. The term post-intensive care syndrome
has been used to refer to the constellation of psychiatric,
cognitive, and physical function problems present in
ICU survivors, including those with ARDS [34]. The re-
lationship of systemic immunosuppression or hyperme-
tabolism to late-phase skeletal muscle dysfunction in
patients with ARDS deserves further attention.
Pharmacologic and nutritional contributions to early- and
late-phase muscle wasting
Some of the earliest reports of muscle weakness in crit-
ically ill patients associated the presence of what is now
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cular blockade (NMB) [35, 36]. However, more current
evidence suggests that glucocorticoids, but not NMB, is
associated with ICUAW [20, 23, 37]. In the most com-
pelling recent evidence, a randomized controlled trial of
the neuromuscular blocker cisatracurium for severe
ARDS, the incidence of ICUAW, measured by MMT, at
hospital discharge was no different from control [38].
The association of ICUAW with glucocorticoids ap-
pears stronger than that of NMB. Increased duration of
glucocorticoid use is independently associated with in-
creased myosin degradation in the skeletal muscles of
critically ill patients on mechanical ventilation [39]. In
the ARDS Network Long Term Outcomes study, which
followed ARDS survivors enrolled in ARDS network tri-
als, both dose of corticosteroid and ICU length of stay
were associated with reduced functional outcomes at 6
and 12 months [20]. These results suggest that drugs or
interventions in the ICU, even administered for short
durations, can impact long-term outcomes. Other data
supporting the importance of glucocorticoids in muscle
wasting in ARDS include the fact that the glucocorticoid
receptor is an upstream modulator of muscle ring finger 1
(MuRF1) activation [40], an important contributor to
early-phase muscle wasting (see ‘The ubiquitin-proteasome
system and muscle ring finger 1’ section). Overall, the avail-
able data suggest that both endogenous and exogenous
glucocorticoids contribute to muscle dysfunction in ARDS.
The role of nutrition in muscle weakness in critical ill-
ness and its contribution to muscle wasting is controver-
sial, although recent evidence suggests that increased
caloric intake during the early phase does not prevent
late-phase muscle dysfunction. In the long-term follow-up
of patients with ARDS in the EDEN (early versus delayed
enteral nutrition) trial, muscle functional outcomes were
unchanged between the two arms at 6 and 12 months [6].
Emerging evidence suggests that early parenteral nutrition
(PN) is detrimental for muscle function in these patients
[41]. The currently available data suggest that early and
full caloric nutrition, either enteral [42] or parenteral [41],
does not reduce the incidence of ICUAW in critically ill
patients, although future investigation is warranted. Nutri-
tional factors may be more important for improving
muscle mass when administered during the late phase.
Early- and late-phase muscle dysfunction in acute
respiratory distress syndrome: underlying
mechanisms
Mechanisms of early-phase muscle wasting
As mentioned above, the cardinal feature of early-phase
muscle dysfunction is atrophy, driven by inflammation
and disuse. The net balance of protein synthesis and
degradation determines myofiber size. Therefore, atro-
phy can occur through increased protein degradation,reduced protein synthesis, or both. In most experimental
models of muscle atrophy, increased muscle protein deg-
radation - not reduced protein synthesis - accounts for
the loss of muscle mass [43], although some controversy
remains [44]. With regard to ARDS-associated muscle
dysfunction, both increased protein degradation and re-
duced protein synthesis contribute to early-phase atro-
phy, although the former mechanism predominates. In
the largest recent study measuring protein synthesis and
degradation in critically ill patients (which included, but
was not limited to, patients with ARDS), rectus femoris
cross-sectional area decreased by 18 % over 10 days. In
this study, patients in the early phase (day 1) showed re-
duced protein synthetic rates compared with fasted con-
trols. At this time point, muscle protein degradation
predominated over protein synthesis. By day 7, protein
synthetic rate had increased compared with day 1 and
fasted controls, likely an attempt of the muscle to re-
cover from the massive protein degradation and atrophy
during the inflammation-driven early phase, although
the balance remained favoring ongoing atrophy [45].
In recent years, three major pathways have emerged as
the primary regulators of muscle atrophy: the calpain-
caspase system, the ubiquitin-proteasome system (UPS),
and the autophagy-lysosome system (autophagy) [43,
46]. All have been implicated in inflammation and disuse
atrophy, but their relative contributions and inter-
relationships during the early phase of muscle wasting in
ARDS remain incompletely understood.
Inflammation-driven atrophy
Both pro- and anti-inflammatory cytokines are present
in the lungs and plasma of patients with ARDS [47].
Many of these pro-inflammatory cytokines are associated
with muscle atrophy in humans and rodents, including
tumor necrosis factor-alpha [48], interleukin (IL)-6 [49],
IL-1β, and others [50, 51]. Muscle atrophy occurring via
inflammatory cytokines classically requires activation of
the transcription factor NF-κB (nuclear factor kappa
light chain enhancer of activated B cells) [52–54], which
in turn can increase muscle protein degradation, leading
to rapid limb and respiratory muscle myofiber atrophy.
In lung-injured mice, marked early muscle atrophy oc-
curs along with lung inflammation [16]. NF-κB activa-
tion in skeletal muscle is necessary for initiating the
muscle atrophy during this early phase [55]. These data
suggest that systemic mediators, such as inflammatory
cytokines or other soluble factors that activate NF-κB,
are important in the early phase of muscle atrophy in
ARDS. These muscle proteolytic pathways may exist in
order to provide nutritional substrates to an organism
under major stress, such as massive infection or injury.
In addition to promoting muscle protein degradation,
pro-inflammatory cytokines may promote atrophy through
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[56], although this concept has received less attention.
Disuse-driven atrophy
There is little doubt that disuse contributes to the limb
muscle atrophy associated with ARDS, given the pro-
found limb and diaphragm disuse that characterizes
these patients. In fact, recent work suggests that bed
rest may ‘prime’ skeletal muscle for atrophy by
increasing the expression of muscle surface TLR4 (Toll-
like receptor 4) receptors, which, when activated, can
promote atrophy [57, 58].
However, both animal models and human data support
the concept that muscle wasting associated with lung in-
jury is phenotypically different from that induced by im-
mobility alone. A recent report of healthy persons
confined to bed rest for one week documented a 4 %
loss of lean body mass [57]. In a study of critically ill
patients on mechanical ventilation, muscle mass loss
was approximately 12 % [45] over that same time
period. Likewise, in an animal model of hind-limb
immobilization, an approximately 5 % muscle mass loss
of the tibialis anterior muscle was seen at day 3.5 [59],
and we find an approximately 22 % muscle mass loss in
the tibialis anterior of lung-injured mice at this time
point [16]. Collectively, these data support the concept
that disuse atrophy contributes to the early phase of
wasting, but less so than inflammation-driven atrophy.
Molecular targets for attenuating muscle atrophy in the
early phase
The ubiquitin-proteasome system and muscle ring
finger 1 Animal models and emerging human data sug-
gest that the UPS plays a prominent role in the early
phase of limb and diaphragmatic muscle wasting in
ARDS. We and others have shown that the UPS-
mediated atrophy is prominent in the early phase of
muscle wasting in lung-injured mice [16, 55, 60]. The E3
ligase MuRF1, which coordinates the ubiquitination of
myosin heavy chain (MyHC) and other contractile pro-
teins for proteasomal degradation [61], is necessary for
early-phase atrophy in this model. Support for the im-
portance of this mechanism in ICUAW is the finding
that selective MyHC degradation is a salient pathologic
feature of critical illness myopathy [62]. Others have
shown that 20S proteasome activity is upregulated in the
vastus lateralis of patients on mechanical ventilation,
which was also associated with upregulation of the fork-
head box o (FoxO) transcription factors, MuRF1, and
other atrophy-promoting genes [39]. In recent work
evaluating serial biopsies in mechanically ventilated pa-
tients, the only consistent change in protein expression
was in MuRF1 and atrogin 1 expression, both of which
were downregulated over time [45], supporting theobservation that this pathway is activated in the early
phase. Another study reported reduced MuRF1 levels in
the muscles of critically ill patients, although the varying
time points for muscle biopsies limit the interpretation
of this finding [63]. The currently available human and
animal data suggest that the UPS plays a prominent role
in the early phase of muscle atrophy in ARDS. As thera-
peutic agents targeting proteins involved in UPS-
mediated atrophy are developed and tested [64], their
use in the early phase of ARDS-associated muscle wast-
ing should be considered.
Autophagy Briefly, macroautophagy (autophagy) is a
ubiquitous process present in multiple cell types in
which cellular proteins and cytoplasm are degraded and
recycled via lysosomes. A focus on autophagy in skeletal
muscle is relatively underexplored [65]. Increased au-
tophagic flux can cause atrophy, although inhibition of
autophagic flux can also induce atrophy, potentially
through upregulation of the UPS [65, 66]. Interestingly,
both the UPS and autophagy pathways can be regulated
by the same FoxO transcription factors [67].
Evidence suggests that autophagy is involved in ARDS-
associated muscle wasting. Diaphragmatic disuse due to
mechanical ventilation in brain-dead humans is associated
with the rapid appearance of autophagosomes and
autophagy-related genes and proteins [68]. This finding
could be due to either increased flux or a block in distal
autophagy processing. In a pig model (combining mech-
anical ventilation, endotoxin, NMB, and corticosteroids),
significant limb muscle atrophy was associated with re-
duction in critical autophagy genes and proteins [69].
In a prospective study of 600 patients in the EPaNIC
(Early Parenteral Nutrition Completing Enteral Nutrition
in Adult Critically Ill Patients) trial, 122 of whom under-
went muscle biopsy, those randomly assigned to late PN
had a reduced incidence of ICUAW compared with
those with early PN; this result was associated with an
increased LC3II-to-LC3I ratio, a marker of autophago-
some formation [41]. These data suggest that autophagy
induction is associated with improved muscle function.
The role of autophagy during the early phase of
muscle wasting in ARDS is complex, given that either
accelerated or impaired autophagy may be deleterious to
muscle function. Details regarding the role of autophagy
and its relationship with the UPS are still emerging, and
more work is needed to determine the role of autophagy
in the early phase of muscle wasting in ARDS. Other
types of muscle autophagy, including microautophagy
[70] and chaperone-mediated autophagy [71], also de-
serve future investigation in this context.
Caspases and calpains Caspases and calpains are early
mediators in the breakdown of sarcomeric proteins that
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pathway. Caspases and calpains have been investigated
more extensively in both endotoxin- and mechanical
ventilation-induced diaphragmatic dysfunction but not
(to our knowledge) in animal models of lung injury.
Supinski and colleagues [72] showed that calpain, cas-
pase, and proteasome activity are upregulated in the dia-
phragm of endotoxin-treated mice. Likewise, diaphragm
calpain activation peaks early (24 h) in the cecal ligation
mouse model of sepsis. Co-administration of eicosapen-
toic acid prevented the loss of specific force-generating
capacity in the diaphragm and prevented calpain activa-
tion [73, 74]. Others have shown that mechanical venti-
lation in humans causes atrophy and increased caspase 9
activity in diaphragm fibers [75]. As such, calpains and
caspases remain attractive potential targets for interven-
tion in the early phase of muscle wasting.
Neuropathy and other pathologies as potential therapeutic
targets in the early phase
As mentioned above, polyneuropathy is found in a sub-
set of patients with ICUAW. Critical illness polyneurop-
athy affects distal axonal sensory and motor nerves,
which may lead to myofiber atrophy and contribute to
weakness independent of atrophy. Histologically, periph-
eral nerves with [76, 77] or without [78] axonal degener-
ation have been described. The polyneuropathy in patients
without nerve degeneration has been proposed to be due
to a transient negative shift in voltage dependence of so-
dium channel fast inactivation leading to reduced excit-
ability of the nerve, demonstrated in both rats and
humans [79].
Autonomic dysregulation, which may be present in
many patients with severe critical illness, may also con-
tribute to polyneuropathy [80]. With this in mind, there
has been recent interest in using β-blockade in patients
with septic shock [81] as a way to attenuate sympathetic
over-activation. Interestingly, stimulation of skeletal
muscle β receptors leads to muscle hypertrophy through
stimulating protein synthesis [82]. Therefore, muscle
function should be incorporated into clinical trial design
of future investigations of β-blockade in critical illness.
Epineurial and endneurial vascular leak [83] causing
nerve edema is another proposed mechanism. Hypergly-
cemia, often characteristic of severe critical illness, could
further impair nerve or muscle microcirculation [84].
This hypothesis may explain why intensive insulin ther-
apy has been associated with a reduced incidence of
ICUAW [85, 86]. Interestingly, the glucose transporter-4
(GLUT4) receptor, which modulates glucose uptake into
muscle, appears mislocalized in patients with critical ill-
ness myopathy [87].
Additionally, reduced muscle membrane excitability is
a common finding on electromyographic studies [23]. Aseries of studies has shown impaired sarcoplasmic
reticulum calcium handling and impaired sodium chan-
nels in muscles of denervated and steroid-treated ro-
dents [88–90], but to our knowledge this has not been
studied in the context of lung injury. Owing to altered
metabolism or increased muscle fatigue, muscle mito-
chondrial injury [91, 92] sustained during the early phase
may contribute to muscle dysfunction.Molecular targets for attenuating muscle atrophy in the
late phase
Ongoing active muscle proteolysis through increased
protein degradation does not appear to be a major con-
tributing factor of weakness during the late phase. The
massive inflammation-induced protein degradation has
subsided at this time point [16, 45]. Therefore, therapies
directed at attenuating muscle proteolysis are less likely
to benefit as much as when administered during the
early phase.
In contrast, enhancing protein synthesis may be useful
during the late phase. Two studies suggest that there is
actually already increased protein synthesis in the late
phase. One study showed muscle activation of the pro-
synthesis AKT-mTOR-S6k (AKT-mammalian target of
rapamycin-ribosomal protein S6 kinase) pathway of crit-
ically ill patients from muscle biopsies that were ob-
tained predominantly in the late phase [63]; a second
study showed increased protein synthesis in the muscles
of critically ill patients at day 7 [45]. This may be a com-
pensatory mechanism to recover from the early phase,
and studies are needed to determine whether augment-
ing protein synthesis pathways can improve muscle mass
during the late phase. Therefore, we propose that late-
phase therapies to improve muscle mass focus on enhan-
cing protein synthesis or other factors to enhance myofi-
ber size, such as through the myostatin pathway [93].Neuropathy and other pathologies as potential therapeutic
targets in the late phase
Evidence suggests that denervation injury may persist
into the late phase. In a cohort of mechanically venti-
lated critically ill patients, muscle biopsies at about day
12 revealed upregulation of the muscle acetylcholine re-
ceptor γ mRNA, a marker of muscle denervation [39].
Late-phase wasting may also exist due to persistence of
some factors initiated during the early phase, such as
disuse, nerve or NMJ injury, excitation contraction un-
coupling, inflammatory myopathy, or mitochondrial
dysfunction.
Additional targets during the late phase include en-
hancing muscle regeneration by targeting muscle stem
(satellite) cell activation/repair [94]. Additionally, enhan-
cing autophagy, as a way to ‘clean up’ the misfolded
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early phase, may theoretically benefit.
Many questions remain about the relationship of the
early phase to the late phase. For instance, is late-phase
wasting due to persistent injuries sustained in the early
phase or are the two phases mechanistically independ-
ent? Is late-phase wasting purely a reflection of a return
to a pre-hospital level of reduced muscle function in pa-
tients with underlying neuromyopathies or sarcopenia?
Answering these questions will clarify potential therapies
to improve muscle function in ARDS survivors. Figure 2
illustrates potential clinical factors and mechanisms as-
sociated with early- and late-phase muscle wasting in
ARDS.
Currently available therapeutic approaches
Insulin administration and tight glycemic control appear
to reduce ICUAW [85], although this approach has been
tempered with the results of the NICE-SUGAR (Normo-
glycemia in Intensive Care Evaluation and Surviving
Using Glucose Algorithm Regulation) trial, which sug-
gested an increased risk of death in the tight glycemic
control arm, possibly due to hypoglycemia [95]. PerhapsFig. 2 Mediators of acute respiratory distress syndrome (ARDS)-induced mu
of the early phase, which is driven fundamentally by inflammation and disu
exacerbate atrophy (blue arrow) and independently cause muscle dysfunct
promising potential early-phase therapy. The late phase is marked by cessatio
treatments at this time point will differ. Mediators of the late phase may
muscle homeostasis following the early phase. Late-phase dysfunction m
NMJ, neuromuscular junction; SR Ca+, sarcoplasmic reticulum calcium; UPstrategies that reduce hyperglycemia without the risk of
hypoglycemia will reduce the incidence of ICUAW.
Currently, early mobilization/rehabilitation is the most
readily available therapy for the attenuation of ICUAW.
Evidence has demonstrated that early rehabilitation of
critically ill patients is safe and has the benefit of im-
proving other outcomes in addition to muscle strength
[96–99]. Emerging evidence suggests that passive load-
ing of the leg in a rat model of mechanical ventilation
and paralysis prevented atrophy and degradation of my-
osin [100]. In a small study of mechanically ventilated
critically ill patients, passive movement of the leg atten-
uated loss of specific force (but not atrophy) measured
by single-fiber contraction [101]. We have recently
shown that a model of early mobilization in lung-
injured mice attenuates the MuRF1-mediated loss of
muscle mass and force during the early phase, through
an NF-κB-mediated mechanism [102]. This suggests
that early mobility may attenuate the inflammation-
induced atrophy in the early phase. As such, early
mobilization (even passive movement) remains the best
available therapy for critically ill patients to attenuate
early- and late-phase muscle wasting in ARDS.scle dysfunction. Skeletal muscle atrophy is the most universal feature
se. Other factors such as neuropathic injury and medications can
ion. Therefore, inhibiting muscle protein degradation is the most
n of inflammation-induced muscle proteolysis and therefore potential
involve persistence of some early-phase injuries or a failure to regain
ay be compounded by underlying pre-ARDS neuromuscular defects.
S, ubiquitin-proteasome system
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safe and effective, there are limitations to its adoption,
and implementation worldwide remains low [103, 104].
Neuromuscular electrical stimulation (NMES) may de-
velop as an alternative therapy [105, 106], particularly
for those who cannot participate in active physical ther-
apy. In a small study, NMES attenuated type 2 myofiber
atrophy, which was associated with relocalization of the
GLUT4 receptor and improved glucose metabolism [87].
Further research is certainly warranted for this potential
therapy.
Conclusions
As new therapies for inhibiting muscle protein degrad-
ation become available [64], it will be critical to adminis-
ter them early in critically ill patients. As we propose
that muscle atrophy is the most universal feature of
ICUAW and that neuropathy will also lead to down-
stream myofiber atrophy, therapies that attenuate muscle
protein degradation during the early phase have the
highest theoretical benefit to improve in-hospital and
long-term outcomes. Investigators interested in the early
treatment of ARDS, such as the Prevention and Early
Treatment of Lung Injury (PETAL) Network, could con-
sider approaches that aim to attenuate the early phase of
muscle wasting in patients with ARDS. This approach
may open a new paradigm of therapies in ARDS, a syn-
drome that imparts a profound and lasting effect on the
musculoskeletal system.
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